Cargando…

Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity

BACKGROUND: Mosquitoes serve as the vector of canine heartworm (Dirofilaria immitis), which represents a significant and persistent threat to canine health. A reduction in the longevity and/or reproductive success of mosquitoes that take a blood meal from fluralaner-treated dogs may consequently red...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Christopher Charles, Normile, Dorothy, Gamble, Sheryl, Guerino, Frank, Dzimianski, Michael T., Moorhead, Andrew Riddell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142166/
https://www.ncbi.nlm.nih.gov/pubmed/37106394
http://dx.doi.org/10.1186/s13071-023-05682-8
_version_ 1785033549398671360
author Evans, Christopher Charles
Normile, Dorothy
Gamble, Sheryl
Guerino, Frank
Dzimianski, Michael T.
Moorhead, Andrew Riddell
author_facet Evans, Christopher Charles
Normile, Dorothy
Gamble, Sheryl
Guerino, Frank
Dzimianski, Michael T.
Moorhead, Andrew Riddell
author_sort Evans, Christopher Charles
collection PubMed
description BACKGROUND: Mosquitoes serve as the vector of canine heartworm (Dirofilaria immitis), which represents a significant and persistent threat to canine health. A reduction in the longevity and/or reproductive success of mosquitoes that take a blood meal from fluralaner-treated dogs may consequently reduce the local transmission of heartworm and prevent new infections. A novel secondary effect of an oral formulation of the ectoparasiticide fluralaner (Bravecto(®)) against a laboratory strain of the mosquito Aedes aegypti, a potential major vector of canine heartworm, was investigated in this study. METHODS: Six dogs were administered a single dose of fluralaner orally in the form of Bravecto(®) Chews (at the labeled fluralaner dose of 25 mg/kg body weight), while six control dogs received no treatment. Mosquitoes were fed on blood that was collected from each dog prior to treatment and weekly for 15 weeks post-treatment to assess the continued effects of fluralaner as its serum level decreased. Mosquito fitness was assessed by three parameters: rate of successful blood-feeding, survival, and egg laying. RESULTS: Successful blood-feeding rate was similar between control and treatment groups. In the fluralaner treatment, mosquito survival was significantly reduced within the first 24 h after blood-feeding, for the first 12 weeks post-treatment of the dogs (efficacy range = 33.2–73.3%). Survival of mosquitoes up until a potentially heartworm-infective timepoint (14 days post-blood-feeding) was significantly reduced in the fluralaner-treated group at several timepoints (1, 2, 5, 11, 12, 13, 14, and 15 weeks post-treatment; efficacy range = 49.4–91.4%), but was less consistently reduced at the other timepoints. Egg laying by mosquitoes was almost completely suppressed for the first 13 weeks following treatment of the dogs with fluralaner (treatment efficacy ≥ 99.8%). CONCLUSIONS: Mosquitoes fed blood from fluralaner-treated dogs experienced a significant reduction in survival and fecundity. These findings support the potential for a reduction in heartworm transmission directly by lethal effects on the vector and indirectly through a reduction of the local vector population when mosquitoes are exposed to animals treated with fluralaner. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-05682-8.
format Online
Article
Text
id pubmed-10142166
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101421662023-04-29 Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity Evans, Christopher Charles Normile, Dorothy Gamble, Sheryl Guerino, Frank Dzimianski, Michael T. Moorhead, Andrew Riddell Parasit Vectors Research BACKGROUND: Mosquitoes serve as the vector of canine heartworm (Dirofilaria immitis), which represents a significant and persistent threat to canine health. A reduction in the longevity and/or reproductive success of mosquitoes that take a blood meal from fluralaner-treated dogs may consequently reduce the local transmission of heartworm and prevent new infections. A novel secondary effect of an oral formulation of the ectoparasiticide fluralaner (Bravecto(®)) against a laboratory strain of the mosquito Aedes aegypti, a potential major vector of canine heartworm, was investigated in this study. METHODS: Six dogs were administered a single dose of fluralaner orally in the form of Bravecto(®) Chews (at the labeled fluralaner dose of 25 mg/kg body weight), while six control dogs received no treatment. Mosquitoes were fed on blood that was collected from each dog prior to treatment and weekly for 15 weeks post-treatment to assess the continued effects of fluralaner as its serum level decreased. Mosquito fitness was assessed by three parameters: rate of successful blood-feeding, survival, and egg laying. RESULTS: Successful blood-feeding rate was similar between control and treatment groups. In the fluralaner treatment, mosquito survival was significantly reduced within the first 24 h after blood-feeding, for the first 12 weeks post-treatment of the dogs (efficacy range = 33.2–73.3%). Survival of mosquitoes up until a potentially heartworm-infective timepoint (14 days post-blood-feeding) was significantly reduced in the fluralaner-treated group at several timepoints (1, 2, 5, 11, 12, 13, 14, and 15 weeks post-treatment; efficacy range = 49.4–91.4%), but was less consistently reduced at the other timepoints. Egg laying by mosquitoes was almost completely suppressed for the first 13 weeks following treatment of the dogs with fluralaner (treatment efficacy ≥ 99.8%). CONCLUSIONS: Mosquitoes fed blood from fluralaner-treated dogs experienced a significant reduction in survival and fecundity. These findings support the potential for a reduction in heartworm transmission directly by lethal effects on the vector and indirectly through a reduction of the local vector population when mosquitoes are exposed to animals treated with fluralaner. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13071-023-05682-8. BioMed Central 2023-04-28 /pmc/articles/PMC10142166/ /pubmed/37106394 http://dx.doi.org/10.1186/s13071-023-05682-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Evans, Christopher Charles
Normile, Dorothy
Gamble, Sheryl
Guerino, Frank
Dzimianski, Michael T.
Moorhead, Andrew Riddell
Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title_full Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title_fullStr Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title_full_unstemmed Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title_short Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
title_sort treatment of dogs with bravecto(®) (fluralaner) reduces mosquito survival and fecundity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142166/
https://www.ncbi.nlm.nih.gov/pubmed/37106394
http://dx.doi.org/10.1186/s13071-023-05682-8
work_keys_str_mv AT evanschristophercharles treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity
AT normiledorothy treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity
AT gamblesheryl treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity
AT guerinofrank treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity
AT dzimianskimichaelt treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity
AT moorheadandrewriddell treatmentofdogswithbravectofluralanerreducesmosquitosurvivalandfecundity